Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.14USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,856
52-wk High
$2.14
52-wk Low
$1.05

Select another date:

Wed, Apr 4 2018

BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer

* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER

BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Cellectar Reports 2017 Financial Results

* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma

* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA

BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma

* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions

* CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING

BRIEF-Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131

* CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131

BRIEF-Cellectar Biosciences posts Q3 loss of $0.26 per share

* Cellectar Biosciences reports third quarter 2017 financial and corporate performance

BRIEF-Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma

* Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences announces new preclinical data

* ‍New preclinical data suggest that Cellectar Biosciences' PDC platform provides enhanced outcomes in combination with external radiation​

Select another date: